Get to know our clinical trials
Phase I/II, open-label study of HST-1011 administered in monotherapy and in combination with an anti-PD1 antibody in patients with advanced solid tumors
EL OBJETIVO PRINCIPAL DE ESTE ESTUDIO ES DETERMINAR LA SEGURIDAD Y LA ACTIVIDAD PRELIMINAR DE HST-1011 CUANDO SE ADMINISTRA SOLO Y EN COMBINACIÓN CON CEMIPLIMAB-RWLC PARA PACIENTES CON CÁNCER. EL ESTUDIO RECOGERÁ CIERTOS ANÁLISIS DE LABORATORIO DE SU SANGRE Y/O TUMOR PARA QUE EL PROMOTOR PUEDA COMPRENDER MEJOR CÓMO ESTÁ FUNCIONANDO EL FÁRMACO.
Technical Summary
- PHASE I/II, OPEN-LABEL STUDY OF HST-1011 ADMINISTERED IN MONOTHERAPY AND IN COMBINATION WITH AN ANTI-PD1 ANTIBODY IN PATIENTS WITH ADVANCED SOLID TUMORS.
- Code EudraCT: 2023-503731-18-00
- Protocol number: Clin-001
- Promoter: HOTSPOT Therapeutics
- Molecule/Drug: HST-1011
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.